Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2014 Mar;62(3):482-8.
doi: 10.1111/jgs.12687. Epub 2014 Feb 10.

Comorbidity burden and guideline-concordant care for breast cancer

Gretchen Kimmick  1 , Steven T Fleming, Susan A Sabatino, Xiao-Cheng Wu, Wenke Hwang, J Frank Wilson, Mary Jo Lund, Rosemary Cress, Roger T Anderson; Centers for Disease Control and Prevention National Program of Cancer Registry Patterns of Care Study Group
Affiliations
Multicenter Study

Comorbidity burden and guideline-concordant care for breast cancer

Gretchen Kimmick et al. J Am Geriatr Soc. 2014 Mar.

Abstract

Objectives: To explore the relationship between level and type of comorbidity and guideline-concordant care for early-stage breast cancer.

Design: Cross-sectional.

Setting: National Program of Cancer Registry (NPCR) Breast and Prostate Cancer Patterns of Care study, which re-abstracted medical records from 2004 in seven cancer registries.

Participants: Individuals with stage 0-III breast cancer.

Measurements: Multicomponent guideline-concordant management was modeled based on tumor size, node status, and hormone receptor status, according to consensus guidelines. Comorbid conditions and severity were measured using the Adult Comorbidity Evaluation Index (ACE-27). Multivariate logistic regression models determined factors associated with guideline-concordant care and included overall ACE-27 scores and 26 separate ACE comorbidity categories, age, race, stage, and source of payment.

Results: The study sample included 6,439 women (mean age 58.7, range 20-99; 76% white; 44% with no comorbidity; 70% estrogen- or progesterone-receptor positive, or both; 31% human epidermal growth factor receptor 2 positive). Care was guideline concordant in 60%. Guideline concordance varied according to overall comorbidity burden (70% for none; 61% for minor; 58% for moderate, 43% for severe; P < .05). In multivariate analysis, the presence of hypertension (odds ratio (OR) = 1.15, 95% confidence interval (CI) = 1.01-1.30) predicted guideline concordance, whereas dementia (OR = 0.45, 95% CI = 0.24-0.82) predicted lack of guideline concordance. Older age (≥ 50) and black race were associated with less guideline concordance, regardless of comorbidity level.

Conclusion: When reporting survival outcomes in individuals with breast cancer with comorbidity, adherence to care guidelines should be among the covariates.

Keywords: breast cancer; comorbidity; guideline concordance.

PubMed Disclaimer

References

    1. Louwman WJ, Janssen-Heijnen MLG, Houterman S, et al. Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: A population-based study. Eur J Cancer. 2005;41:779–785. - PubMed
    1. Land LH, Dalton SO, Jorgensen TL, et al. Comorbidity and survival after early breast cancer. A review Crit Rev Oncol Hematol. 2012;8:196–205. - PubMed
    1. Hawfield A, Lovato J, Covington D, et al. Retrospective study of the effect of comorbidity on use of adjuvant chemotherapy in older women with breast cancer in a tertiary care setting. Crit Rev Oncol Hematol. 2006;59:250–255. - PubMed
    1. Garg P, Rana F, Gupta R, et al. Predictors of toxicity and toxicity profile of adjuvant chemotherapy in elderly breast cancer patients. Breast J. 2009;15:404–408. - PubMed
    1. Lee L, Cheung WY, Atkinson E, et al. Impact of comorbidity on chemotherapy use and outcomes in solid tumors: A systematic review. J Clin Oncol. 2011;29:106–117. - PubMed

Publication types